Polypharmacology of Approved Anticancer Drugs

No Thumbnail Available
Files
There are no files associated with this item.
Date
2017
Authors
Lisitsa, Andrey
Knight, Richard A.
Melino, Gerry
Antonov, Alexey V.
Editors
Contact
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
URI (citable link)
DOI (citable link)
10.2174/1389450117666160301095233
ArXiv-ID
International patent number
Link to the license
In Copyright
EU project number
Project
Open Access publication
Collections
Biologie
Restricted until
Title in another language
Research Projects
Organizational Units
Journal Issue
Publication type
Journal article
Publication status
Published
Published in
Current Drug Targets ; 18 (2017), 5. - pp. 534-543. - Bentham Science. - ISSN 1389-4501. - eISSN 1873-5592
Abstract
The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Polypharmacology, tyrosine kinase inhibitors, histone deacetylase inhibitors, DNA topoisomerase inhibitors, tamoxifen, drug targets, rational design of multitarget drugs
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690AMELIO, Ivano, Andrey LISITSA, Richard A. KNIGHT, Gerry MELINO, Alexey V. ANTONOV, 2017. Polypharmacology of Approved Anticancer Drugs. In: Current Drug Targets. Bentham Science. 18(5), pp. 534-543. ISSN 1389-4501. eISSN 1873-5592. Available under: doi: 10.2174/1389450117666160301095233
BibTex
@article{Amelio2017Polyp-56667,
  year={2017},
  doi={10.2174/1389450117666160301095233},
  title={Polypharmacology of Approved Anticancer Drugs},
  number={5},
  volume={18},
  issn={1389-4501},
  journal={Current Drug Targets},
  pages={534--543},
  author={Amelio, Ivano and Lisitsa, Andrey and Knight, Richard A. and Melino, Gerry and Antonov, Alexey V.}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/56667">
    <dc:creator>Amelio, Ivano</dc:creator>
    <dc:creator>Melino, Gerry</dc:creator>
    <dcterms:title>Polypharmacology of Approved Anticancer Drugs</dcterms:title>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:language>eng</dc:language>
    <dcterms:abstract xml:lang="eng">The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.</dcterms:abstract>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>2017</dcterms:issued>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-23T14:42:45Z</dc:date>
    <dc:contributor>Knight, Richard A.</dc:contributor>
    <dc:contributor>Amelio, Ivano</dc:contributor>
    <dc:contributor>Lisitsa, Andrey</dc:contributor>
    <dc:contributor>Antonov, Alexey V.</dc:contributor>
    <dc:creator>Knight, Richard A.</dc:creator>
    <dc:creator>Antonov, Alexey V.</dc:creator>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/56667"/>
    <dc:creator>Lisitsa, Andrey</dc:creator>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:contributor>Melino, Gerry</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2022-02-23T14:42:45Z</dcterms:available>
    <dc:rights>terms-of-use</dc:rights>
  </rdf:Description>
</rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Contact
URL of original publication
Test date of URL
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
No
Refereed
Yes